From Adiposity to Hepatic Health: Exploring the Pleiotropic Clinical Impact of Semaglutide
Naim Alkhouri; Gema Frühbeck
MATERIALS AVAILABLE
Teaser Video
Full Recording
15:30 - 15:36
CEST
OP160
ORAL PRESENTATION
Weight-independent benefits of semaglutide on histology and non-invasive tests in participants with biopsy-defined metabolic dysfunction-associated steatohepatitis: Post hoc analysis of the ESSENCE trial part 1
Philip N. Newsome1,2; Matthew J. Armstrong3; Igor Bakulin4; Adel Belloum5; Anja Geerts6,7; Jacob George8; Ewa Janczewska9; Niels Krarup5; Chun-Jen Liu10,11; Håvard Midgard12; Vlad Ratziu13; Mary Rinella14; Michael Roden15,16,17; Arun J. Sanyal18; Jörn M. Schattenberg19; Mohamed Tawfik5; Thea Vestergaard5; Elisabetta Bugianesi20; on behalf of the ESSENCE Study Group
MATERIALS AVAILABLE
Slide
Tuesday, 07 October 2025
10:12 - 10:24
CEST
MP218
POSTER
Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo
Mary E. Rinella1; Manal F. Abdelmalek2; Elisabetta Bugianesi3; Laurent Castera4,5; Kristiane A. Engebretsen6; Jacob George7; Wah Kheong Chan8; Niels Krarup6; Michelle T. Long6; Philip N. Newsome9,10; Cláudia P. Oliveira11; Georgios Papatheodoridis12; Ahsan Shoeb6; Salvatore Petta13; Michael Roden14,15,16; Arun J. Sanyal17; Yusuf Yilmaz18; Vlad Ratziu19; on behalf of the ESSENCE study group